[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345247-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345247-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","liposomal-nanotherapeutics-for-cancer-treatment-targeted-delivery-and-immunotherapy","Liposomal nanotherapeutics for cancer treatment - Targeted delivery and immunotherapy","","Cancer represents a major global health crisis, with more than 270 cancer types and an estimated 13 million deaths by 2030. The multifaceted pathophysiology complicates diagnosis and makes treatment difficult due to high costs, toxicity, off-target effects, and comorbidities. This review examines liposomes as nanocarriers for targeted cancer therapy, emphasizing formulation advances that improve site-specific release, cellular uptake, and tumor-selective effectiveness while addressing limitations such as endosomal entrapment and storage instability.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/liposomal-nanotherapeutics-for-cancer-treatment-targeted-delivery-and-immunotherapy/345247/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/liposomal-nanotherapeutics-for-cancer-treatment-targeted-delivery-and-immunotherapy/345247.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes cancer a major global health crisis, according to the abstract?","Question",{"text":63,"@type":64},"Cancer has more than 270 types and is estimated to claim about 13 million lives by 2030, making it the second leading cause of death worldwide.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are current cancer treatments still challenging?",{"text":68,"@type":64},"They remain challenging due to higher costs, toxicity, off-target effects, and comorbid conditions.",{"name":70,"@type":61,"acceptedAnswer":71},"What advantages do liposomal nanotherapeutics offer for cancer treatment?",{"text":72,"@type":64},"Liposomes can improve drug efficacy, enable controlled site-specific release, enhance cellular uptake, reduce systemic toxicity, and help overcome tumor-induced resistance mechanisms.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345247,1790305489,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Advancing Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improved Patient Outcomes-Review  \nLiposomal nanotherapeutics for cancer treatment: Targeted delivery and immunotherapy  \nInternational Journal of Immunopathology and Pharmacology Volume 40: 1–21  \n© The Author(s) 2026  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/03946320261438337](DOI: 10.1177/03946320261438337)[ ](DOI: 10.1177/03946320261438337)[journals.sagepub.com/home/iji](journals.sagepub.com/home/iji)  \nMahin Zubair Butt 1*, Zahra Tariq 1*, Maryam Imran 1, Ahood A. Al-Eidan2, Shahzadi Mahjabeen 1, Seerat Fatima 1, Ghayyas ud Din3,4, Sumaira Anjum 1, Elham Abdullatif M. Sharif5 and Wisam Nabeel Ibrahim5  \nAbstract  \nCancer has become a major global health crisis and the second leading cause of death worldwide. With over 270 different types, it is estimated to claim 13 million lives by 2030. The complex pathophysiology of cancer, with its diverse genetic, epigenetic, and biochemical pathways, complicates the diagnostic criteria. Therapeutic approaches such as surgical interventions, radiotherapy, chemotherapy, and immunotherapy have been developed. However, the treatment is still challenging due to higher costs, toxicity, off-target effects, and comorbid conditions. Over the decades, liposomes, based on their particle size, surface charge, lipid composition, and lamellarity, have been explored for different therapeutic modalities for other cancers. They offer unique advantages, including improved drug efficacy, controlled site-specific release, enhanced cellular uptake, reduced systemic toxicity, and greater capacity to overcome tumor-induced resistance mechanisms. Researchers have explored liposomal treatment modalities for breast, lung, adenocarcinoma, ovarian, liver, fibrosarcoma, glioblastoma, and brain cancers. The tumor targeting drugs, for example, doxorubicin and paclitaxel, are delivered at the tumor microenvironment (TME) by passive and active transport, utilizing both the enhanced permeability and resistance (EPR) effect and cellular targets, for example, receptors, proteins, and organelles, in response to physical stimuli, for example, temperature, pH, fluid pressure, and nutrient and metabolic regulation. However, liposomes also face several limitations, including endosomal entrapment, heterogeneous targeting, suboptimal uptake by antigen-presenting cells (APCs), and storage instability. This review focuses on the advancementsin liposomal nanocarriers for targeted cancer therapy. It emphasizes the evolution of their formulations to overcome potential limitations, making them highly tumor-specific and effective.  \nKeywords  \nliposomes, cancer, stimuli, EPR effect, tumor Microenvironment, nanocarriers  \nDate received: 12 December 2025; accepted: 17 March 2026  \n1 Kinnaird College for Women, Lahore, Pakistan  \n2Department of Biology, College of Science, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia  \n3Guangdong Provincial Key Laboratory of Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China  \n4Chinese Academy of Sciences, Beijing, China  \n5Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar  \n*These authors contributed equally to this work.  \nCorresponding authors:  \nSumaira Anjum, Department of Biotechnology, Kinnaird College for Women University, 93-Jail Road, G.O.R 1, Lahore 54000, Pakistan. Email: [sumaira.anjum@kinnaird.edu.pk](sumaira.anjum@kinnaird.edu.pk)  \nWisam Nabeel Ibrahim, Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, University Street, Doha 2713, Qatar.  \n[Email: w.ibrahim@qu.edu.qa](Email: w.ibrahim@qu.edu.qa)  \nCreative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 L","cbCaifUc5353pzBZ","https://ap.wps.com/l/cbCaifUc5353pzBZ","pdf",1381841,21,"English","# Abstract\n## Hallmarks of cancer\n## Cancer burden and prognosis\n## Pathophysiology stages","[{\"question\":\"What makes cancer a major global health crisis, according to the abstract?\",\"answer\":\"Cancer has more than 270 types and is estimated to claim about 13 million lives by 2030, making it the second leading cause of death worldwide.\"},{\"question\":\"Why are current cancer treatments still challenging?\",\"answer\":\"They remain challenging due to higher costs, toxicity, off-target effects, and comorbid conditions.\"},{\"question\":\"What advantages do liposomal nanotherapeutics offer for cancer treatment?\",\"answer\":\"Liposomes can improve drug efficacy, enable controlled site-specific release, enhance cellular uptake, reduce systemic toxicity, and help overcome tumor-induced resistance mechanisms.\"}]","Liposomal nanotherapeutics for cancer treatment - Targeted delivery and immunotherapy | PDF",1790056946,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/682453928918213f765dd5faaf3ae0ee.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/258f6aea62eabe03864f261db406a945.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1620cb0f69c1ba9bb9c0b5dfab96135.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/668cefcbf9c8da5333bc8589187fdc4f.webp",980,1306]